News You Can Use… Robert Vincent, PharmD PGY1 Pete Koval, PharmD Cone Health Family Medicine September, 2016

New Drug Approval Qbrelis ™ lisinopril oral solution First available ACE-I solution 1mg/ml strength Indicated for the treatment of: HTN in adults and children age ≥ 6 Adjunct therapy for heart failure Acute MI in adults

New Drug Approval Troxyca ER ® (oxycodone/naltrexone) Indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment Formulated to deter abuse when crushed and administered orally or intranasally Not for PRN use

New Vaccine Approval Afluria ® flu vaccine Inactivated influenza virus Available in quadrivalent (age 5 and up) and trivalent Trivalent formulation has Needleless injector Uses narrow fluid stream to penetrate skin Eligible age: years Provides non-inferior immune response to traditional needle

Investigational Drug Esketamine (s-katamine) receives two novel indications for the treatment of depression: Treatment-resistant depression Major depressive disorder with imminent risk of suicide Esketamine is a N-methyl-D-aspartate (NMDA) receptor antagonist NOT yet approved. Remains in studies for these two new novel indications.

Approved Biosimilars Erelzi ® (etanercept-szzs) biosimilar for Enbrel ® (etanercept) Indicated for ankylosing spondylitis, plaque psoriasis, psoriatic and rheumatoid arthritis Inflectra ® (infliximab-dyyb) biosimilar for Remicade ® (infliximab) Indicated for ankylosing spondylitis, plaque psoriasis, psoriatic and rheumatoid arthritis and UC/Crohn’s

Drug Prices Mylan to offer generic Epi-Pen at half the price Generic drug company (Mylan) offering “generic” of its own branded product $300 price tag (3x the 2007 price) and about ½ the price of the “brand name Epi-Pen” made by this same company